The global lentiviral vector CDMO market is set to witness a growth rate of 8% in the next 5 years. Growing demand for gene and cell therapies; expanding pipeline of gene therapy products; ...

Conclusion The lentiviral vector market is expected to grow significantly in the coming years, driven by advancements in gene therapy and increased investment in biotechnology. As the market evolves, ...

To help you keep track of all the Illinois-related comings, goings and flirtations in the transfer portal, we've provided some handy charts below.

Professor Amrolia selected ViroCell to manufacture the lentiviral vector for this novel CAR T-cell therapy based on its track record for delivering high quality vector.

Lightweight-seat specialist Mirus is marking its tenth anniversary with its largest Hamburg presence yet.

GRAND FORKS — This page tracks players who have entered the NCAA men's college hockey transfer portal and who have committed to new programs during the 2025 offseason. Sources are linked (x).

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform.

Frank Mathias, Chief Executive Officer of OXB, said: "We are delighted that Boehringer Ingelheim is using OXB’s proprietary lentiviral vector manufacturing technology for the clinical development of ...

Lentiviral vectors (LVVs) are becoming increasingly prominent in the advanced therapy space, according to Rentschler Biopharma.

Germany-based Merck KGaA has concluded the acquisition of Mirus Bio for €500m ($600m), enhancing its viral vector bioprocessing capabilities. The companies entered a definitive agreement in May ...

Germany-based Merck KGaA has concluded the acquisition of Mirus Bio for €500m ($600m), enhancing its viral vector bioprocessing capabilities.

The addition of Mirus Bio’s leading transfection reagents strengthens MilliporeSigma's upstream portfolio and allows for an integrated viral vector manufacturing offering.